2022 EQA Scheme Registration is Now Open
Please log in to your EMQN account to purchase EQA schemes for 2022. We highly recommend registering for schemes as soon as possible as some schemes may become over subscribed due to high demand.
Interested in joining EMQN? Membership is free! You can click the link below to visit our scheme catalogue to view the available schemes in 2022.
If you have any questions, please do contact us at office@emqn.org.
Membership Scheme Changes Starting in 2022
EMQN have recently undergone an organisational review, and as a result our membership scheme is evolving and adapting to fit in with both the needs of our members and our organisation. From 2022, we will be offering our membership at no yearly cost.
Click below to read EMQN’s full statement on our membership scheme changes as well as what’s new for 2022!
We are a not-for-profit organisation promoting quality in genomic testing by establishing, harmonising and disseminating best practice.
We provide ISO 17043 accredited External Quality Assessment (EQA) or Proficiency Testing (PT) schemes which are designed to test the whole analytical process of a molecular diagnostics laboratory including the ability to interpret data in the light of clinical information supplied with a referral, and to produce a clear and accurate report.
EQAs for SARS-Cov-2 and other respiratory viruses open for registration
We have EQAs for SARS-Cov-2 only, or in conjunction with other major respiratory viruses (RSV, Influenza) available for registration. Use the button below to browse our scheme catalogue.
The latest news and press releases
Publication of Provisional Results from 2021 Postnatal Constitutional CNV Detection EQA - https://t.co/FOHp6CSajG
Validated genotypes published for 2021 Molecular Pathology EQA schemes - https://t.co/sqFetyNMsd
Validated genotypes published for 2021 Pharmacogenetics EQA scheme - https://t.co/BiuRuXcKJ8
2022 EQA Scheme Registration is Now Open - https://t.co/kNhD4lGvND
2022 EQA Scheme Registration is Now Open - https://t.co/YB5zR7vC5s